Category

Clinical

[article_filters]

October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease

October 15, 2024

July 2, 2024: MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

July 2, 2024

June 24, 2024: MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer

Business-Clinical

June 24, 2024

April 22, 2024: MaaT Pharma to Hold Annual General Meeting on May 28, 2024

April 22, 2024

April 15, 2024: MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

April 15, 2024

April 8, 2024: MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

April 8, 2024

March 19, 2024: MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

March 19, 2024

March 12, 2024: MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

March 12, 2024

March 5, 2024: MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma

March 5, 2024

February 29, 2024: MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

February 29, 2024

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact